Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) Publication of Research Note
London, New York, 21 September 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), is pleased to note the publication of a new analyst
Tiziana Life Sci PLC (TILS.L) Clinical Study with Nasally Administered Foralumab
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.L) Submission of Patent Application
Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy
Kunwar Shailubhai, CEO of Tiziana Life Sciences (NASDAQ:TLSA, AIM:TILS) Interview
Zak Mir speaks with Kunwar Shailubhai, CEO of Tiziana Life Sciences, are the markets, prospective investor understanding the business model?. As is often the case the focus is on a company